期刊文献+

伊立替康在晚期胃癌中的作用与地位 被引量:5

CPT-11 iIn the function and position in the stomach cancer in later period
下载PDF
导出
摘要 目的评价伊立替康在晚期胃癌化疗中的临床疗效及毒副作用。方法将52例晚期胃癌患者随机分为两组,A组应用伊立替康联合希罗达,B组应用伊立替康联合替加氟,均化疗2个周期以上,观察疗效及毒副作用。结果两组患者近期疗效比较,A组有效率为50%,B组有效率为46.15%,差异无统计学意义;毒副反应A组恶心、呕吐发生率、腹泻发生率较B组高,B组血小板减少较A组高(P<0.05)具有统计学意义。结论以CPT-11为基础的化疗方案对晚期胃癌有良好的疗效,且毒副反应可以耐受,CPT-11有望在晚期胃癌的治疗中起重要的作用。 Objective Evaluate CPT-11 the clinical curative effect in the stomach cancer chemotherapy and poison side effect in later period.Methods 52 later period stomach cancer the sufferer is random divided into 2 sets,The A set is applied CPT-11 Unite Xeloda,The B set is applied CPT-11 Unite ftorafur,All chemotherapy 2 periods are above,observe curative effect and poison side effect.Results Two sets of sufferers in the near future curative effect compare,the A set is efficient to is 50%,the B set is efficient for 46.15%,and the difference has no statistics to learn meaning;Poison pair the reaction A set is disgusted,vomit incidence rate,diarrhea incidence rate compare B set high,B set the blood platelets reduce compare A set high.Conclusion The CPT-11-based chemotherapy project has good curative effect to the stomach cancer in later period,and the poisonous pair reaction can bear to be subjected to,CPT-11 has the under medical treatment of the stomach cancer to hope in the later period to contain important function.
作者 林春平
出处 《中国现代药物应用》 2011年第4期3-4,共2页 Chinese Journal of Modern Drug Application
关键词 伊立替康 希罗达 替加氟 晚期胃癌 评价 CPT-11 Xeloda ftorafur Later period stomach cancer Evaluate
  • 相关文献

参考文献7

  • 1王肇炎.胃癌的药物治疗[J].肿瘤研究与临床,2006,18(8):574-576. 被引量:16
  • 2Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organi- zation for Research and Treatment of Cancer, National Cancer Insti- tute Of the United States, National Cancer Institute of Canada. J Natl Cancer Inst.2000.92 ( 3 ) :205-216.
  • 3周际吕.实用肿瘤内科学.人民卫生出版社,2003:292-461.
  • 4Kang YK, Kang W K, Shin DB,et 81. Cpccitabjne/ci platin versus 5-fluOr0uracil/cjsplaIin as first-line therapy in patients with advanced gastric cancer: a randomised phaseⅢnoninferiority trial. Ann Onco1,2009,20 (4) :666-673.
  • 5Boku N, Ohtsu A, Shimada Y, et al. Phase Ⅱ study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol, 1999,17 ( 1 ) :319-323.
  • 6潘敦,李良庆.伊立替康联合替加氟治疗晚期胃癌的临床观察[J].中国现代医药杂志,2010,12(3):9-11. 被引量:3
  • 7Sena K,Morotome Y,Baba O,et al. Gene expression of growth dif- ferentiation factors in the developing periodontium of rat molars. J Dent Res,2003,82 ( 3 ) : 166-17.

二级参考文献3

  • 1Sena K, Morotome Y,Baba O,et al.Gene expression of growth differentiation factors in the developing periodontium of rat molars [J]. J Dent Res, 2003,82(3) : 166-171.
  • 2Suzuki S,Harada N,Takeo Y,et al.Bi-weekly irinotecan hydchloride and cisplatin as a second-line chemotherapy for patiewith advanced gastric cancer [J].Gan To Kagaku Ryoho,2007,13: 2245-2248.
  • 3Farhat FS.A general review ofthe role of irinotecan (CPT-11) the treatment of gastric cancer[J].Med Oncol, 2007,24(2) : 137-146.

共引文献17

同被引文献14

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部